Pharmaceutical patents and the right to health – Portugal and Brazil

  1. Ruben Bahamonde Delgado 1
  1. 1 Universidade Autónoma de Lisboa
    info

    Universidade Autónoma de Lisboa

    Lisboa, Portugal

    ROR https://ror.org/01ryrwk91

Journal:
JANUS.NET

ISSN: 1647-7251

Year of publication: 2022

Volume: 13

Issue: 1

Pages: 171-189

Type: Article

DOI: 10.26619/1647-7251.13.1.11 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: JANUS.NET

Abstract

The defence of the patent system’s legitimacy, namely in the pharmaceutical field, is consolidated, although it is not exempt from criticism. Historically, when the patent law, a legal monopoly right, is confronted with the right of access to health, which includes the right to the medicines necessary for its care, the mechanisms that have been established are scarce and weak. Nonetheless, one must recognize due merit in the search for a balance between the exclusive right of the holder of the legal monopoly and the right of the community to generalized access to medicines necessary to fulfil the right to health. In the current context of the covid-19 disease, where access to health care for all countries, rich and poor, is at stake, it seems that there is a greater will to make the right to health prevail over the property right of the holder of a pharmaceutical patent.

Bibliographic References

  • Bahamonde, Ruben (2016). El derecho de la competencia y los acuerdos de transferencia de tecnología. Aranzadi.
  • Bartels, Hans Georg (2020). Global Challenges Division, IP and COVID-19, WHO, WIPO, WTO Study. Promoting Access to Medical Technologies and Innovation, Geneva. https://www.who.int/publications/i/item/9789240008267
  • Carvalho Filho, José dos Santos, Severo and Sousa Dabés Leão, Simone Letícia (2019). A Concretização do direito à saúde pela jurisprudência do Supremo Tribunal Federal, Revista de Direito Sociais e Políticas Públicas, V. 5, No. 2: 25-28.
  • Couto Gonçalves, Luís M. (2005). Manual de Direito Industrial, Patentes. Marcas. Concorrência Desleal: Almedina.
  • Cullet, Philipe (2003). Patent and medicines: the relationship between TRIPS and the human right to health, International Affairs, 79, I: 139-160.
  • Durão Barroso, J.M. (2021). «Propriedade Intelectual e Vacinas anti COVID-19», Boletim. Ordem dos Advogados, no. 32: 65-66.
  • Fernández-Nóvoa, Carlos, Otero Lastres, José Manuel and Botana Agra, Manuel (2017). Manual de la Propiedad Industrial, 3rd ed., Marcial Pons.
  • Gold ER, Kaplan W, Orbinski J, Harland-Logan S, N-Marandi S (2010). «Are Patents Impeding Medical Care and Innovation?» PLoS Med 7(1): e1000208. https://doi.org/10.1371/journal.pmed.1000208
  • Gomes Canotilho, J. J., Moreira, Vital (2014). Constituição da República Portuguesa Anotada, Vol. I, 4rd Ed., Coimbra Editora.
  • Helfer, Laurence R (2015). «Pharmaceutical Patents and the Human Right to Health. The Contested Evolution of the Transnational Legal Order on Access to Medicines, Transnational Legal Orders» Terence. C. Halliday & GREGORY Shaffer, ed.: 311 -339.
  • Human Rights Watch (2021). «Seven Reasons the EU is Wrong to Oppose the TRIPS Waiver». https://www.hrw.org/news/2021/06/03/seven-reasons-eu-wrong-opposetrips-waiver
  • Miranda, Jorge, Medeiros, Rui (2010). Constituição Portuguesa Anotada, Vol. I, 2nd Ed., Coimbra Editora.
  • Monge, Cláudia (2019). «O direito fundamental à protecção da saúde», Revista Electrónica de Direito Público, Vol. 6, no. 1: 75-100.
  • Nunes, A. J. Avelâs, Marques, J. P. Remédio, Abreu, J.M Coutinho de, Cunha, LP (2009). «A inconstitucionalidade das patentes “pipe-line” brasileiras (ARTICLES 230 and 231 do CÓDIGO DA PROPRIEDADE INDUSTRIAL DE 1996)», Revista Electrónica do IPB, Patentes Pipeline, Ed. Especial, Instituto Brasileiro de Propriedade Intelectual.
  • Orsi, Fabienne, D´Almeida, Cristina, Hasenclever, Lia, Camara, Mamadou, Tigre, Paulo and Coriat, Benjamin (2007). TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges, AIDS, Vol. 21, Issue (15), pp. 1997-2003, DOI: 10.1097/QAD.0b013e328273bbe4 .
  • Palmela Fidalgo, Vítor (2016). As licenças Compulsórias de Direitos de Propriedade Industrial. Almedina.
  • Pérez Martinez, Miriam (2018). «Derecho de Patentes Versus Derecho de Defensa de la Competencia en la Unión Europea: ¿Una relación de complementariedad?», Cuadernos de Derecho Transnacional, Vol. 10, no. 1: 372-393.
  • Polônio, Carlos Alberto (2006). «Patentes farmacêuticas e acesso a medicamentos: regras comerciais, direito à saúde e direitos humanos», Revista de Direito Sanitário, São Paulo, V.7, n. 1/2/3 p. 163-182. https://doi.org/10.11606/issn.2316-9044.v7i1-3p163- 182
  • Pontes, C.E.C. (2017). «Patentes de medicamentos e a indústria farmacêutica nacional: Estudo dos depósitos feitos no Brasil», Revista Produção e Desenvolvimento (RPD), v. 3, n.º 2: 38-51.
  • Remédio Marques, J.P. (2011). Contratos de Direito de Autor e de Direito Industrial, (Org. Ferreira de Almeida, Carlos, Couto Gonçalves, Luís e Trabuco, Cláudia, Almedina: 399- 400.
  • Samuel Cross, Yeanuk Rho, Henna Reddy, Toby Pepperrell, Florence Dodgers, Thiannon Osborne, Ayolola Eni-Olotu, Rishi Banerjee, Sarai Keestra (2021). «Who funded the research behind the Oxford-AstraZeneca Covid-19 vaccine?». https://doi.org/10.1101/2021.04.08.21255103
  • Sellin, J.A. (2015). «Does One Size Fit All? Patents, the Right to Health and Access to Medicines». Neth Int Law Rev 62: 445–473.
  • Sousa e Silva, Pedro (2011). Direito Industrial, Noções Fundamentais, 1st ed., Almedina.
  • Hoen, E. F. M., Veraldi, J., Toebes, B. and Hogerzeil, H. V. (2018). «Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016», Bulletin of the World Health Organization 96: 186–187. http://dx.doi.org/10.2471/BLT.17.19936
  • Tudor, Elena Cristina (2018). «La cláusula Bolar como excepción a los derechos conferidos por una patente farmacéutica en Europa». Revista de Estudios Europeos, no. 71: 300-308.
Data source: Dialnet